Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E, Bourbouloux E, Mendiola C, Delgado FM, Colin C, Aslanis V, Fumoleau P. Campone M, et al. Among authors: aslanis v. Br J Cancer. 2006 Nov 6;95(9):1161-6. doi: 10.1038/sj.bjc.6603347. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031408 Free PMC article. Clinical Trial.
Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Joel SP, Papamichael D, Richards F, Davis T, Aslanis V, Chatelut E, Locke K, Slevin ML, Seymour MT. Joel SP, et al. Among authors: aslanis v. Clin Pharmacol Ther. 2004 Jul;76(1):45-54. doi: 10.1016/j.clpt.2004.03.008. Clin Pharmacol Ther. 2004. PMID: 15229463 Clinical Trial.
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, Phung D, Herman K, Holyer I, Poulsen KK, Dogterom P, Tantawi S, Zetterberg FR, Jacoby B, Schambye H, Lindmark B. Aslanis V, et al. Cancer Chemother Pharmacol. 2024 Nov;94(5):707-720. doi: 10.1007/s00280-024-04710-3. Epub 2024 Aug 21. Cancer Chemother Pharmacol. 2024. PMID: 39167148 Clinical Trial.
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants.
Aslanis V, Slack RJ, MacKinnon AC, McClinton C, Tantawi S, Gravelle L, Nilsson UJ, Leffler H, Brooks A, Khindri SK, Marshall RP, Pedersen A, Schambye H, Zetterberg F. Aslanis V, et al. Cancer Chemother Pharmacol. 2023 Mar;91(3):267-280. doi: 10.1007/s00280-023-04513-y. Epub 2023 Mar 13. Cancer Chemother Pharmacol. 2023. PMID: 36914828 Free PMC article. Clinical Trial.
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).
Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O'Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T, Dhaliwal K. Gaughan EE, et al. Among authors: aslanis v. Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149. doi: 10.1164/rccm.202203-0477OC. Am J Respir Crit Care Med. 2023. PMID: 35972987 Free PMC article. Clinical Trial.
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K, Huth F, Jin Y, Schiller H, Aslanis V, Heimbach T, He H. Umehara K, et al. Among authors: aslanis v. Drug Metab Pers Ther. 2019 May 30;34(2):/j/dmdi.2019.34.issue-2/dmpt-2018-0042/dmpt-2018-0042.xml. doi: 10.1515/dmpt-2018-0042. Drug Metab Pers Ther. 2019. PMID: 31145690
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
Frey N, Jang JH, Szer J, Illés Á, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S. Frey N, et al. Among authors: aslanis v. Lancet Haematol. 2019 Mar;6(3):e122-e131. doi: 10.1016/S2352-3026(18)30231-X. Epub 2019 Jan 29. Lancet Haematol. 2019. PMID: 30704923 Clinical Trial.
15 results